Potassium (potassium 6.5mmol) effervescent tablets BPC 1968

국가: 영국

언어: 영어

출처: MHRA (Medicines & Healthcare Products Regulatory Agency)

유효 성분:

Potassium bicarbonate; Potassium acid tartrate

제공처:

potassium 6.5mmol) effervescent tablets BPC 1968 (Actavis UK Ltd

ATC 코드:

A12BA04

INN (International Name):

Potassium bicarbonate; Potassium acid tartrate

복용량:

500mg ; 300mg

약제 형태:

Effervescent tablet

관리 경로:

Oral

수업:

No Controlled Drug Status

처방전 유형:

Valid as a prescribable product

제품 요약:

BNF: 09020103; GTIN: 5012617010391

환자 정보 전단

POTASSIUM TABLETS EFFERVESCENT BPC 1968
Potassium Hydrogen Carbonate and Potassium Hydrogen Tartrate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE.
•
Keep this leaflet. You may need it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you. Do not pass it on to
others. It may harm
them, even if their symptoms are the same as yours.
INDEX
1.
WHAT POTASSIUM TABLETS EFFERVESCENT BPC 1968 ARE AND WHAT THEY ARE
USED
FOR
2.
BEFORE YOU TAKE
3.
HOW TO TAKE
4.
POSSIBLE SIDE EFFECTS
5.
HOW TO STORE
6.
FURTHER INFORMATION
1.
WHAT POTASSIUM TABLETS EFFERVESCENT BPC 1968 ARE AND WHAT THEY ARE
USED
FOR
Potassium tablets effervescent BPC 1968 belong to a group of medicines
called
potassium supplements, they may be used to treat:
•
all cases of potassium reduction resulting from:
-
intensive or prolonged treatment with diuretics (water tablets e.g.
furosemide or
hydrochlorothiazide)
-
digitalis treatment (medicines for the heart such as digoxin)
-
corticosteroid or carbenoxolone sodium treatment
-
advanced liver disease
-
chronic kidney disease
-
Cushing's syndrome (this condition can cause muscle weakness, obesity
and
brittle bones)
-
diabetic ketosis (poorly controlled diabetes, patients may feel
unwell, have severe
stomach pains or fruity smelling breath)
-
renal tubular or metabolic acidosis (too much acid in the body)
-
a diet low in salt or potassium
-
conditions causing prolonged or chronic diarrhoea and vomiting.
2.
BEFORE YOU TAKE
DO NOT TAKE
Potassium tablets effervescent BPC 1968 and
TELL
your doctor if you have:
•
HIGH
levels of
POTASSIUM
in the blood (hyperkalaemia)
•
LOW
levels of
CHLORIDE
in the blood (hypochloraemia)
•
severely impaired
KIDNEY
function with little or no urine production or high levels of
waste products such as urea in the blood
•
untreated
ADDISON’S DISEASE
•
acute DEHYDRATION
•
large areas of
INJURY
to BODY TISSUE
such as severe burns.
CHECK WITH YOUR DOCTOR OR PHARMACIST
before takin

제품 특성 요약

OBJECT 1
POTASSIUM TABLETS EFFERVESCENT
Summary of Product Characteristics Updated 15-Jan-2016 | Accord-UK Ltd
1. Name of the medicinal product
POTASSIUM TABLETS EFFERVESCENT BPC 1968
2. Qualitative and quantitative composition
Each tablet contains 500mg Potassium Hydrogen Carbonateand 300mg
Potassium Hydrogen Tartrate
equivalent to 6.5mmol of potassium (K
+
)
3. Pharmaceutical form
White uncoated tablets.
4. Clinical particulars
4.1 Therapeutic indications
Indicated in all cases of potassium depletion resulting from intensive
or prolonged diuretic therapy, an
inadequate dietary potassium intake, and those receiving digitalis -
here the elderly population are a
special risk. A lack of cellular potassium in the diet can increase
the toxic effect of digitalis.
Other indications include corticosteroid therapy, use of carbenoxolone
sodium, advanced hepatic
cirrhosis, chronic renal disease, Cushing's syndrome, diabetic
ketosis, renal tubular or metabolic acidosis,
patients on a low-salt diet and in conditions requiring potassium
supplementation due to prolonged or
chronic diarrhoea and vomiting.
4.2 Posology and method of administration
_Posology_
Tablets should be dissolved in half a tumbler of cold water before
drinking.
_Adults:_ Usually 4-7 tablets daily (26-45.5mmol K
+
) but dosage should be adjusted to the individual
requirements of the patient, based on clinical and laboratory
evaluations.
_Children:_ At the discretion of the physician.
_Elderly:_ There are no special dosage requirements, but impairment of
renal function should be taken into
account. The elderly require monitoring of serum electrolytes.
_Method of Administration_
To be dissolved in water for oral administration
4.3 Contraindications
• Hyperkalaemia or hyperkalaemic form of familial periodic
paralysis;
• Hypochloraemic states;
• Plasma potassium greater than 5 mmol/L;
• Severe renal impairment (acute or chronic) with anuria, oliguria
or azotemia;
• Untreated Addison's disease;
• Acute dehydration;
• Extensive tissue destruction as